Biography and Research Information
OverviewAI-generated summary
Logan Meurer's research focuses on medical case studies, particularly involving critical care scenarios and novel treatment approaches. Their work includes investigating the emergent use of therapeutic plasma exchange following overzealous intravenous lipid emulsion infusion for local anesthetic systemic toxicity. Another area of study involves the development of new-onset sarcoidosis during B-cell maturation antigen (BCMA)-directed T-cell engager therapy for relapsed/refractory multiple myeloma. Meurer has published two papers with a total of four citations and an h-index of 1. Key collaborators include Gina Drobena, P Ravikumar, and Brooke Yasgur, all from the University of Arkansas for Medical Sciences, with whom Meurer has co-authored publications.
Metrics
- h-index: 1
- Publications: 2
- Citations: 4
Positions
-
Resident Physician 2024–presentUniversity of Arkansas for Medical Sciences Department of Pathology ORCID
Selected Publications
-
New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight (2026)
-
Antidote Worse Than the Poison? Emergent Therapeutic Plasma Exchange After Overzealous Intravenous Lipid Emulsion Infusion During Treatment of Local Anesthetic Systemic Toxicity (2025)
Collaboration Network
Top Collaborators
- Antidote Worse Than the Poison? Emergent Therapeutic Plasma Exchange After Overzealous Intravenous Lipid Emulsion Infusion During Treatment of Local Anesthetic Systemic Toxicity
- Antidote Worse Than the Poison? Emergent Therapeutic Plasma Exchange After Overzealous Intravenous Lipid Emulsion Infusion During Treatment of Local Anesthetic Systemic Toxicity
- Antidote Worse Than the Poison? Emergent Therapeutic Plasma Exchange After Overzealous Intravenous Lipid Emulsion Infusion During Treatment of Local Anesthetic Systemic Toxicity
- Antidote Worse Than the Poison? Emergent Therapeutic Plasma Exchange After Overzealous Intravenous Lipid Emulsion Infusion During Treatment of Local Anesthetic Systemic Toxicity
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
- New-Onset Sarcoidosis During B-cell Maturation Antigen (BCMA)-Directed T-cell Engager Therapy With Teclistamab in Relapsed/Refractory High-Risk Multiple Myeloma: A Case Report and Mechanistic Insight
Similar Researchers
Based on overlapping research topics